hydroxyurea has been researched along with Anaphylaxis in 6 studies
Anaphylaxis: An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Combination therapy blocking both PAF and histamine markedly reduces the severity of peanut-induced anaphylaxis, and thus it may be a potential life-saving therapeutic approach in peanut and, likely, other food-induced anaphylaxis." | 7.75 | Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. ( Arias, K; Baig, M; Chu, D; Colangelo, M; Coyle, A; Goncharova, S; Jordana, M; Vadas, P; Walker, T; Waserman, S, 2009) |
| " A selective and potent 5-LO inhibitor, zileuton (N-1(1-benzo[b]thien-2-ylethyl)-N-hydroxyurea, A-64077) was evaluated in models of airway anaphylaxis, where leukotrienes are a major component." | 7.69 | The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis. ( Bell, RL; Brooks, DW; Carter, GW; Malo, PE; Shaughnessy, TK; Summers, JB, 1994) |
| "Combination therapy blocking both PAF and histamine markedly reduces the severity of peanut-induced anaphylaxis, and thus it may be a potential life-saving therapeutic approach in peanut and, likely, other food-induced anaphylaxis." | 3.75 | Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. ( Arias, K; Baig, M; Chu, D; Colangelo, M; Coyle, A; Goncharova, S; Jordana, M; Vadas, P; Walker, T; Waserman, S, 2009) |
| " A selective and potent 5-LO inhibitor, zileuton (N-1(1-benzo[b]thien-2-ylethyl)-N-hydroxyurea, A-64077) was evaluated in models of airway anaphylaxis, where leukotrienes are a major component." | 3.69 | The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis. ( Bell, RL; Brooks, DW; Carter, GW; Malo, PE; Shaughnessy, TK; Summers, JB, 1994) |
| "Representative nonsteroidal anti-inflammatory drug (NSAID) cyclooxygenase inhibitors such as ibuprofen, naproxen, and indomethacin were used as orally bioavailable scaffolds to design selective 5-lipoxygenase (5-LO) inhibitors." | 1.30 | Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors. ( Bell, RL; Bouska, J; Brooks, CD; Carter, GW; Dellaria, JF; Hulkower, KI; Kolasa, T; Rodriques, KE; Summers, JB, 1997) |
| " In addition, the compound exhibits excellent bioavailability in dogs and monkeys with a relatively long elimination half-life in both the species (6 and 3 h, respectively)." | 1.29 | The properties of A-69412: a small hydrophilic 5-lipoxygenase inhibitor. ( Bell, RL; Bouska, J; Brooks, DW; Carter, GW; Lanni, C; Machinist, J; Malo, PE; Summers, JB; Young, PR, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arias, K | 1 |
| Baig, M | 1 |
| Colangelo, M | 1 |
| Chu, D | 1 |
| Walker, T | 1 |
| Goncharova, S | 1 |
| Coyle, A | 1 |
| Vadas, P | 1 |
| Waserman, S | 1 |
| Jordana, M | 1 |
| Malo, PE | 2 |
| Bell, RL | 4 |
| Shaughnessy, TK | 1 |
| Summers, JB | 4 |
| Brooks, DW | 3 |
| Carter, GW | 4 |
| Bouska, J | 2 |
| Young, PR | 2 |
| Lanni, C | 2 |
| Machinist, J | 1 |
| Kolasa, T | 1 |
| Brooks, CD | 1 |
| Rodriques, KE | 1 |
| Dellaria, JF | 1 |
| Hulkower, KI | 1 |
| Payne, AN | 1 |
| Jackson, WP | 1 |
| Salmon, JA | 1 |
| Nicholls, A | 1 |
| Yeadon, M | 1 |
| Garland, LG | 1 |
6 other studies available for hydroxyurea and Anaphylaxis
| Article | Year |
|---|---|
Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions.
Topics: Allergens; Anaphylaxis; Animals; Arachis; Cholera Toxin; Cimetidine; Disease Models, Animal; Drug Th | 2009 |
The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis.
Topics: Anaphylaxis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bronchoconstriction; Disease Models, | 1994 |
The properties of A-69412: a small hydrophilic 5-lipoxygenase inhibitor.
Topics: Anaphylaxis; Animals; Biological Availability; Blood Proteins; Dogs; Half-Life; Humans; Hydroxyurea; | 1993 |
Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.
Topics: Anaphylaxis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Desig | 1997 |
Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma.
Topics: Anaphylaxis; Animals; Asthma; Benzeneacetamides; Bronchial Diseases; Guinea Pigs; Humans; Hydroxamic | 1991 |
Inhibition of leukotriene biosynthesis in the rat peritoneal cavity.
Topics: Administration, Oral; Anaphylaxis; Animals; Disease Models, Animal; Hydroxyurea; Leukotrienes; Lipox | 1991 |